secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001193125-25-160293
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma appoints Carole Ho and Elizabeth Weatherman to Board of Directors
--------------------------------------------------------------------------------

- Carole Ho (CMO of Denali Therapeutics) and Elizabeth Weatherman (Special LP at Warburg Pincus) appointed effective July 17, 2025.
- Independent board representation increases to >90% following external manager acquisition.
- Both directors determined independent under Nasdaq standards; no family relationships with officers or directors.
- They will receive compensation per Independent Director Compensation Policy detailed in April 2025 Proxy Statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312525160293/0001193125-25-160293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312525160293/d948144d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-160293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer